Company Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.
The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.
It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE.
In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies.
Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development.
The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc.
Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Sep 17, 1991 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 7,570 |
| CEO | Christopher A. Viehbacher |
Contact Details
Address: 225 Binney Street Cambridge, Massachusetts United States | |
| Website | https://www.biogen.com |
Stock Details
| Ticker Symbol | BIIB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000875045 |
| CUSIP Number | 09062X103 |
| ISIN Number | US09062X1037 |
| Employer ID | 33-0112644 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher A. Viehbacher | President, Chief Executive Officer & Director |
| Michael R. McDonnell CPA | Executive Vice President & Chief Financial Officer |
| Susan H. Alexander Esq. | Executive Vice President & Chief Legal Officer |
| Adam Keeney Ph.D. | Executive Vice President & Head of Corporate Development |
| Dr. Ginger Gregory Ph.D. | Executive Vice President & Chief Human Resources Officer |
| Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs |
| Nicole Murphy | Head of Pharmaceutical Operations & Technology |
| Rachid Izzar | Head of Global Product Strategy & Commercialization |
| Robin C. Kramer | Senior Vice President & Chief Accounting Officer |
| Tim Power M.B.A., Ph.D. | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | SCHEDULE 13D | Filing |
| Jan 07, 2025 | 3 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 4 | Filing |
| Nov 04, 2024 | 4 | Filing |
| Nov 04, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 30, 2024 | 8-K | Current Report |